Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Shareholder Meeting (August 2020)
22 slides from Viyash Scientific's shareholder meeting presentation, Aug 25, 2020
Slide 1: A Warm Welcome
A Warm Welcome 35th Annual General Meeting 25-Aug-20
Slide 2: Agenda
Agenda J Seauent & Proven Ability In Life Sciences | avivina ee _ ie oS 1 ~e. _— SY ee ~ ~ Xs ~ ~~, ~A ~ N S. ™~ ‘\ \ ‘\ > N \ N \ \ \ \ o \ \ \ \ \ \ \ \ 1 | | EH } j . / . / . Strategic 7) New Orbit, 7 FY20 - Cruise FY21 - Growth f Developments.” New Possibilities,” phase 7 Catalyst 7 7 Zz 4
Slide 3: Strategic developments
Sequent | & Proven Ability In Life Sciences Strategic developments
Slide 4: Carlyle transaction update
Carlyle transaction update • As announced on May 8, 2020, CA Harbor Investments (The Carlyle Group) entered in Binding Agreement with the existing Promoters of the company to acquire majority stake in SeQuent Scientific Limited • Proposed transaction triggered mandatory open offer by Carlyle Group t
Slide 5: Recent Board changes
Recent Board changes Mr. Narendra Mairpady’s term as Independent Director ended on July 31, 2020 In view of the change in control, Mr. Rajakumar and Dr S. Devendra Kumar ceased to be Non-Executive Directors from August 17, 2020 Mr. Neeraj Bharadwaj and Mr. Rahul Mukim joined the Board on August 17,
Slide 6: A Warm welcome to new Directors
A Warm welcome to new Directors • Managing Director of Carlyle India Advisors Private Limited, • Director at Carlyle India Advisors Private focused on large growth capital & buyout opportunities across Limited, focused on India buyout sectors in India opportunities • Prior Experience: Managing Direc
Slide 7: New Orbit, New Possibilities
New Orbit, New Possibilities 7
Slide 8: Lift Off - A Journey of Excellence
Lift Off - A Journey of Excellence Creation of India’s Largest animal health company, 20th Largest in the World Unique business model driven by strong execution skills API Business Formulations Business Analytical Services • India’s 1st USFDA approved Veterinary • Diversified portfolio of 1,000+ FDF
Slide 9: Geared for next-orbit growth
Geared for next-orbit growth Largest Pureplay 8 Global Animal Health Company Manufacturing Assets 100+ in India, Spain, Germany, Country Presence from India Brazil and Turkey $100 Mn 27 1,000+ Investment in R&D, Commercial APIs FDFs across 12 dosage forms manufacturing & market presence 1,700+ USFDA
Slide 10: Powered Ascent
Powered Ascent ₹ 11,792 Mn 19.6% Revenue from 44.9% ₹ 1,758 Mn 78x ₹ 699 Mn Profit after tax and 4-year CAGR 4-year CAGR EBITDA Jump from operations FY18 minority interest 61x ₹ 1,272 Mn 650bps 14.9% 580bps 5.9% Jump from Cash from Operations improvement EBITDA Margin improvement PAT Margin FY17 vs
Slide 11: FY20 – Cruise Phase
Sequent & Proven Ability In Life Sciences @ | FY20 — Cruise Phase | wc $8880 Fam] 68 20,020, Om WG
Slide 12: FY20 - Operational excellence delivers
FY20 - Operational excellence delivers Industry leading growth with ₹ 11.8 Bn Revenues, Operational excellence +16.4% on YOY basis • Albendazole capacity enhanced by 20% • Formulations delivers strong growth, +14.1% YOY • Operationalised nutritional facility in Spain • Turkey drives growth, +66.9% •
Slide 13: R&D Formulations API
R&D Formulations API 35+ 14+ FDFs in Pipeline APIs in Pipeline 4 1 R&D Centres R&D Centre 10 29 New filings in Filings in US in next 3 years US and EU 13
Slide 14: Financial Performance
Financial Performance All values in ₹ Mn REVENUE EBITDA PAT 11,792 699 13.5% 1,758 43.7% 32.5% 1,327 487 10,393 FY19 FY20 FY19 FY20 FY19 FY20 14
Slide 15: Delivering Consistently over 12 quarters
Delivering Consistently over 12 quarters All values in ₹ Mn Revenue Revenue 3,164 3,006 2,780 2,842 2,819 2,517 2,705 2,352 2,249 2,328 1,942 1,975 11,792 10,393 8,494 6,890 FY17 FY18 FY19 FY20 Q1 Q2 Q3 Q4 EBITDA EBITDA 15.3% 17.0% 13.9% 13.3% 14.3% 13.1% 12.7% 13.2% 10.6% 10.0% 1,758 9.6% 484 511 1
Slide 16: Key Balance Sheet items
Key Balance Sheet items All values in ₹ Mn ROCE* Cash from operations Particulars Mar-20 Mar-19 1,154 1,273 14.9% 11.7% Shareholders' funds 7,428 7,067 7.8% 541 4.0% Minority Interest 447 403 21 Net Debt 2,155 2,532 FY17 FY18 FY19 FY20 FY17 FY18 FY19 FY20 *Adjusted for investments Investments 1,313
Slide 17: FY21- Positive outlook in Challenging environment
FY21- Positive outlook in Challenging environment 17
Slide 18: Covid-19 - Overcoming operational challenges responsibly
Covid-19 - Overcoming operational challenges responsibly Operating challenges Counter measures and Strategic • Intermittent lockdowns actions • Manpower availability • Longer shifts, attendance incentives, safety • Material supply constraints measures, enhanced term & medical • Logistical disruption
Slide 19: Q1 FY21 – Growth momentum continues
Q1 FY21 – Growth momentum continues All values in ₹ Mn REVENUE EBITDA PAT 521 209 3,103 35.4% 82.6% 11.6% 385 115 2,780 Q1 FY 20 Q1 FY 21 Q1 FY 20 Q1 FY 21 Q1 FY 20 Q1 FY 21 19
Slide 20: Key Balance Sheet items
Key Balance Sheet items All values in ₹ Mn Particulars Jun-20 Mar-20 ROCE* Net debt to EBITDA Shareholders' funds 8,070 7,428 17.8% 3.75 14.9% Minority Interest 478 447 11.7% 2.81 7.8% 1.90 Net Debt 1,903 2,155 1.23 4.0% 0.91 Investments 1,723 1,313 Tangible Assets 3,522 3,560 FY17 FY18 FY19 FY20 1Q
Slide 21: Growth Catalyst - FY21
Growth Catalyst - FY21 ▪ Distribution agreement with Zoetis for India – Portfolio of 15 products covering Synergies both their vintage as well as the global brands Consolidation ▪ Acquisition of minority stake in Turkey to be completed by end-September Capacity ▪ Expansion at Vizag facility to facil
Slide 22: THANK YOU
Sequent & Proven Ability in Life Sciences | avivir. : : ’ a : , : ’ , , ’ THANK YOU
SeQuent Scientific — Shareholder Meeting (August 2020) on 6ix